Nele De Meulenaere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nele De Meulenaere has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Dieter Peeters
Department of Pathology Antwerp University Hospital and University of Antwerp Edegem Belgium
1 shared publication- Guy Van Camp
Center of Medical Genetics, University of Antwerp, Antwerp, Belgium
1 shared publication Jan van Meerbeeck
Department of Thoracic Oncology Antwerp University Hospital and University of Antwerp Edegem Belgium
1 shared publication- Janah Vandenhoeck
Center of Medical Genetics University of Antwerp and Antwerp University Hospital Edegem Belgium
1 shared publication Jeroen M. H. Hendriks
Department of Thoracic and Vascular Surgery Antwerp University Hospital Edegem Belgium
1 shared publicationJo Raskin
Department of Thoracic Oncology Antwerp University Hospital and University of Antwerp Edegem Belgium
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (4) , 933-946
Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple diagnostic procedures before a definitive diagnosis can be made. To improve diagnostic accuracy, we developed a DNA methylation‐based biomarker assay capable of distinguishing PM from healthy pleura and other pleural pathologies. Using Infinium EPIC array data, we identified 744 hypermethylated CpG sites in PM as candidate biomarkers. These were validated in silico using external datasets, yielding a high mean AUC of 0.935. Clinical validation was performed using IMPRESS, a novel bisulfite‐free methylation detection technique that enables simultaneous analysis of thousands of CpG sites. A two‐step classifier approach was applied: the first model differentiated tumoral from nontumoral pleura with 89.2% sensitivity and 93.5% specificity, while the second model distinguished PM from pleural metastases with 85.2% sensitivity and 100% specificity. These results demonstrate that our methylation‐based biomarker panel offers a highly accurate and minimally invasive tool for differentiating PM from other pleural conditions, potentially streamlining the diagnostic process and improving clinical decision‐making.
- 14 November 2025
- Published by Wiley in Molecular Oncology
- Vol. 20 (4) , 933-946
Open AccessMethylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Pleural mesothelioma (PM) is a rare and aggressive cancer that often requires multiple diagnostic procedures before a definitive diagnosis can be made. To improve diagnostic accuracy, we developed a DNA methylation‐based biomarker assay capable of distinguishing PM from healthy pleura and other pleural pathologies. Using Infinium EPIC array data, we identified 744 hypermethylated CpG sites in PM as candidate biomarkers. These were validated in silico using external datasets, yielding a high mean AUC of 0.935. Clinical validation was performed using IMPRESS, a novel bisulfite‐free methylation detection technique that enables simultaneous analysis of thousands of CpG sites. A two‐step classifier approach was applied: the first model differentiated tumoral from nontumoral pleura with 89.2% sensitivity and 93.5% specificity, while the second model distinguished PM from pleural metastases with 85.2% sensitivity and 100% specificity. These results demonstrate that our methylation‐based biomarker panel offers a highly accurate and minimally invasive tool for differentiating PM from other pleural conditions, potentially streamlining the diagnostic process and improving clinical decision‐making.